Drug Profile
R 503
Alternative Names: R-503Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Radikal Therapeutics
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Reperfusion injury
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Reperfusion-injury in USA (Parenteral)